While many people have reported positive impacts of GLP-1s, some users have reported brain fog, while others say they experience less pleasure and are less motivated
In the latest wave of popular weight-loss treatments, several types of drugs commonly used to treat type 2 diabetes have been making headlines
The introduction of these pharmacological interventions represents a paradigm shift, acknowledging the biological factors that contribute to obesity and making safe, effective weight loss more attainable
The intersection of semaglutide and ibuprofen usage in patients presents a complex scenario fraught with potential pharmacodynamic and pharmacokinetic interactions that warrant careful consideration
Identifying High-Risk Patients Pre-existing conditions that may increase NAION risk with GLP-1 use include: Diabetes, especially long-standing or poorly controlled Hypertension Hyperlipidemia Sleep apnea History of previous NAION in one eye Age is a significant factor, with individuals over 50 at higher risk
To date, clinical trials and studies have not shown a direct link between Ozempic and an increased risk of breast cancer in humans